Biosimilars Get Their Own FDA Reference ‘Purple Book’

Drug Industry Daily
A A
The FDA for the first time has published a reference list for biologics, known as the Purple Book, that will list all brand products and any biosimilars with which they are interchangeable.

To View This Article:

Login

Subscribe To Drug Industry Daily